UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934


       Date of Report (Date of Earliest Event Reported): November 8, 2004


                              PHARMAFRONTIERS CORP.
                              ---------------------
             (Exact name of registrant as specified in its charter)


                                      TEXAS
                                      -----
                 (State or other jurisdiction of incorporation)


              000-25513                                  760333165
              ---------                                  ---------
     (Commission  File  Number)             (I.R.S. Employer Identification No.)


                    18205 Burkhardt Rd., Tomball Texas, 77377
                    -----------------------------------------
          (Address of principal executive offices, including zip code)


                                 (281) 290-6655
                                 --------------
              (Registrant's telephone number, including area code)



ITEM 8.01.  OTHER EVENTS.

     On  November  8,  2004,  PharmaFrontiers  Corp.  issued  a  press  release
announcing  the  closing  of  its  previously  announced  acquisition  of  Opexa
Pharmaceuticals,  Inc., a Houston-based developer of cell-based therapeutics for
autoimmune  diseases,  initially  targeting  multiple  sclerosis.

ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBIT

     (c)    Exhibits

The following exhibits are to be filed as part of this 8-K:

  EXHIBIT  NO. IDENTIFICATION OF EXHIBIT
  -----------  -------------------------

     99.1      Press  Release  of  PharmaFrontiers Corp. dated November 8, 2004.



                                   SIGNATURES


     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  hereunto  duly  authorized.


                               PHARMAFRONTIERS CORP.


                               By: /s/ David McWilliams
                               -------------------------
                               David McWilliams, Chief Executive Officer


DATE: November 8, 2004



                                  EXHIBIT INDEX

Exhibit No.   Description
- -----------   -----------
99.1          Press Release of PharmaFrontiers Corp. dated November 8, 2004